Company intelligence / Profile preview

Shijishenkang Pharmaceutical Company

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Shiji Shenkang Pharmaceutical is a Beijing-based biotechnology company specializing in the development of innovative drugs for central nervous system (CNS) diseases. The company is primarily recognized for its lead clinical candidate, SK-08, a small molecule derivative of ligustrazine (tetramethylpyrazine) designed to treat acute ischemic stroke. SK-08 has advanced into Phase 3 clinical trials in China, positioning the company as a significant player in the neuroprotective therapy space. Shiji Shenkang maintains strong research ties with the Institute of Materia Medica at the Chinese Academy of Medical Sciences to drive its drug discovery efforts.

Therapeutic areas: CardiovascularNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Institute of Materia Medica, Chinese Academy of Medical Sciences

Beyond the preview

Go deeper on Shijishenkang Pharmaceutical Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shijishenkang Pharmaceutical Company.

Explore the full profile